PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

about

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

Item

http://www.wikidata.org/entity/Q55262520

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

@en

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

@nl

type

Item

label

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

@en

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

@nl

prefLabel

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

@en

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

@nl

P1476

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy

@en

P2093

Barbara Wollenberg

http://www.w3.org/2001/XMLSchema#string

Bernardo S Franklin

http://www.w3.org/2001/XMLSchema#string

Christian Idel

http://www.w3.org/2001/XMLSchema#string

Eicke Latz

http://www.w3.org/2001/XMLSchema#string

Jens Habermann

http://www.w3.org/2001/XMLSchema#string

Julika Ribbat-Idel

http://www.w3.org/2001/XMLSchema#string

Kirstin Plötze-Martin

http://www.w3.org/2001/XMLSchema#string

Ralph Pries

http://www.w3.org/2001/XMLSchema#string

Sabine Bohnet

http://www.w3.org/2001/XMLSchema#string

Timo Gemoll

http://www.w3.org/2001/XMLSchema#string

P2860

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

The blockade of immune checkpoints in cancer immunotherapy

Pembrolizumab for the treatment of non-small-cell lung cancer

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.

Platelets guide the formation of early metastatic niches.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Platelets and angiogenesis in malignancy.

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

CANCER IMMUNOLOGY. The "cancer immunogram".

P304

27460-27470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25446

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29937998

http://www.w3.org/2001/XMLSchema#string

P932

6007942

http://www.w3.org/2001/XMLSchema#string